Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

July 14, 2025

Study Completion Date

August 4, 2025

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

PIPE-307 Dose A

Subjects will receive daily oral doses of PIPE-307

DRUG

PIPE-307 Dose B

Subjects will receive daily oral doses of PIPE-307

DRUG

Placebo

Subjects will receive daily oral matching dose of Placebo

Trial Locations (21)

11042

Neurological Associates of Long Island, P.C., Lake Success

14226

Dent Neurologic Institute, Amherst

30309

Shepherd Center, Atlanta

33761

MS and Neuromuscular Center of Excellence, Clearwater

34105

Aqualane Clinical Research, Naples

37922

Sibyl Wray Neurology PC, Knoxville

63110

Washington University School of Medicine, St Louis

66160

University of Kansas Medical Center, Kansas City

73104

Oklahoma Research Foundation - MS Center of Excellence, Oklahoma City

77030

University of Texas Health Science Center at Houston, Houston

77074

Clinical Trial Network, Houston

79410

Bhupesh Dihenia, MD, PA, Lubbock

80907

Colorado Springs Neurological Associates, Colorado Springs

85004

Xenosciences, Phoenix

85032

Arizona Neuroscience Research, LLC, Phoenix

87106

University of New Mexico/Health Science Center/MIND Imaging Center/MS Specialty Clinic, Albuquerque

94705

Alta Bates Summit Medical Center, Berkeley

98101

Virginia Mason Medical Center, Seattle

98133

UW Medicine MS Center, Seattle

98405

Multicare Neuroscience Center of Washington, Tacoma

02035

Neurology Center of New England P.C., Foxborough

Sponsors
All Listed Sponsors
lead

Contineum Therapeutics

INDUSTRY